VIA
CELG

Vantis Investment Advisers’s Celgene Corp CELG Stock Holding History

Vantis Investment Advisers’s Portfolio CELG Stock Details CELG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-100,000
Closed -$12.4M – 17
2017
Q1 		$12.4M Buy
+100,000
New +$12M 5.93% 6

Other funds holding CELG

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Edgewood Management
Edgewood Management Greenwich, Connecticut $15.5B AUM 9.67% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Vantis Investment Advisers's CELG Position: Q2 2017 in Review

Vantis Investment Advisers sold out of Celgene Corp (CELG) in Q2 2017, closing a stake of 100,000 shares — an estimated $12.4M sold.

Vantis Investment Advisers first reported a position in CELG in Q1 2017 and held it in 1 quarter. The position peaked at $12.4M in Q1 2017. 1,428 funds tracked by Wall St. Rank hold CELG as of Q2 2017.

  • Vantis Investment Advisers reported no remaining Celgene Corp position as of Q2 2017 after selling out during the quarter.
  • Vantis Investment Advisers sold 100,000 Celgene Corp shares in Q2 2017, an estimated $12.4M.
  • Vantis Investment Advisers first reported a position in Celgene Corp in Q1 2017 and held it in 1 quarter.
  • Vantis Investment Advisers's Celgene Corp position peaked at $12.4M in Q1 2017.
  • 1,428 funds tracked by Wall St. Rank held Celgene Corp as of Q2 2017.

Based on Vantis Investment Advisers's 13F filing for Q2 2017, filed 14 Aug 2017.